Literature DB >> 21955663

Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush.

Gert Meijer1, Jacco Steenhuijsen, Matthieu Bal, Katrien De Jaeger, Danny Schuring, Jacqueline Theuws.   

Abstract

PURPOSE: Local recurrence rates are high in patients with locally advanced NSCLC treated with 60 to 66 Gy in 2 Gy fractions. It is hypothesised that boosting volumes with high SUV on the pre-treatment FDG-PET scan potentially increases local control while maintaining acceptable toxicity levels. We compared two approaches: threshold-based dose painting by contours (DPBC) with voxel-based dose painting by numbers (DPBN).
MATERIALS AND METHODS: Two dose painted plans were generated for 10 stage II/III NSCLC patients with 66 Gy at 2-Gy fractions to the entire PTV and a boost dose to the high SUV areas within the primary GTV. DPBC aims for a uniform boost dose at the volume encompassing the SUV 50%-region (GTV(boost)). DPBN aims for a linear relationship between the boost dose to a voxel and the underlying SUV. For both approaches the boost dose was escalated up to 130 Gy (in 33 fractions) or until the dose limiting constraint of an organ at risk was met.
RESULTS: For three patients (with relatively small peripheral tumours) the dose within the GTV could be boosted to 130 Gy using both strategies. For the remaining patients the boost dose was confined by a critical structure (mediastinal structures in six patients, lungs in one patient). In general the amount of large brush DPBC boosting is limited whenever the GTV(boost) is close to any serial risk organ. In contrast, small brush DPBN inherently boosts at a voxel-by-voxel basis allowing significant higher dose values to high SUV voxels more distant from the organs at risk. We found that the biological SUV gradients are reasonably congruent with the dose gradients that standard linear accelerators can deliver.
CONCLUSIONS: Both large brush DPBC and sharp brush DPBN techniques can be used to considerably boost the dose to the FDG avid regions. However, significantly higher boost levels can be obtained using sharp brush DPBN although sometimes at the cost of a less increased dose to the low SUV regions.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21955663     DOI: 10.1016/j.radonc.2011.08.048

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

Review 1.  Personalized radiotherapy treatment planning based on functional imaging.

Authors:  Malgorzata Skórska; Tomasz Piotrowski
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-15

Review 2.  Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review.

Authors:  Marta Cremonesi; Laura Gilardi; Mahila Esmeralda Ferrari; Gaia Piperno; Laura Lavinia Travaini; Robert Timmerman; Francesca Botta; Guido Baroni; Chiara Maria Grana; Sara Ronchi; Delia Ciardo; Barbara Alicja Jereczek-Fossa; Cristina Garibaldi; Roberto Orecchia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-05       Impact factor: 9.236

Review 3.  Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation.

Authors:  Jing Zeng; Stephen R Bowen
Journal:  Semin Radiat Oncol       Date:  2021-04       Impact factor: 5.934

4.  Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.

Authors:  Malene Martini Clausen; Anders Elias Hansen; Michael Lundemann; Christian Hollensen; Tobias Pommer; Per Munck Af Rosenschöld; Annemarie Thuri Kristensen; Andreas Kjær; Fintan J McEvoy; Svend Aage Engelholm
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481

Review 5.  Towards multidimensional radiotherapy: key challenges for treatment individualisation.

Authors:  Iuliana Toma-Dasu; Alexandru Dasu
Journal:  Comput Math Methods Med       Date:  2015-03-05       Impact factor: 2.238

6.  Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.

Authors:  Jing Liu; Chengqiang Li; Man Hu; Jie Lu; Xiaorong Shi; Ligang Xing; Xindong Sun; Zheng Fu; Jinming Yu; Xue Meng
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

7.  Technical Issues of [(18)F]FET-PET Imaging for Radiation Therapy Planning in Malignant Glioma Patients - A Review.

Authors:  F Walter; C la Fougère; C Belka; M Niyazi
Journal:  Front Oncol       Date:  2012-10-04       Impact factor: 6.244

8.  Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.

Authors:  Soléakhéna Ken; Laure Vieillevigne; Xavier Franceries; Luc Simon; Caroline Supper; Jean-Albert Lotterie; Thomas Filleron; Vincent Lubrano; Isabelle Berry; Emmanuelle Cassol; Martine Delannes; Pierre Celsis; Elizabeth Moyal Cohen-Jonathan; Anne Laprie
Journal:  Radiat Oncol       Date:  2013-01-02       Impact factor: 3.481

9.  Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.

Authors:  Malene M Clausen; Anders E Hansen; Per Munck Af Rosenschold; Andreas Kjaer; Annemarie T Kristensen; Fintan J McEvoy; Svend A Engelholm
Journal:  Radiat Oncol       Date:  2013-11-07       Impact factor: 3.481

10.  Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Bart Reymen; Aniek J G Even; Anne-Marie C Dingemans; Michel Oellers; Joachim E Wildberger; Felix M Mottaghy; Marco Das; Esther G C Troost; Philippe Lambin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.